SomaLogic

What SomaLogic does

SomaLogic is a Boulder, Colorado-based protein biomarker discovery and clinical diagnostics company founded in 2000 that built its business around its proprietary SOMAmer (Slow Off-rate Modified Aptamer) chemistry. The company operates the SomaScan Platform, which uses chemically modified DNA aptamers to measure up to 11,000 proteins simultaneously from a 55-µL plasma or serum sample, covering roughly half of the human proteome across a 10-log dynamic range without sample pre-treatment, with industry-leading reproducibility (median CV of approximately 5%). Complementary products include the SomaScan Select 4K Assay for targeted applications, the KREX high-plex antibody profiling technology for immunoproteomics, and SomaSignal Tests as research-use biomarker panels across cardiovascular, neurodegeneration, oncology, and metabolic disease areas.

SomaLogic commercializes this technology through a fee-for-service SomaScan Assay Services operation running out of a CLIA-certified, CAP-accredited laboratory in Boulder, a global network of Authorized Sites providing regional access, direct sales of Single SOMAmer Reagents to platform operators, and data consulting services. Customers include large pharmaceutical trial sponsors (Bristol Myers Squibb, Novo Nordisk, Gilead, Pfizer, Novartis), national genomics and biobank programs (Genomics England, PRECISE-SG100K), academic medical centers, and research consortia. The company has accumulated 3+ billion proteomic measurements, 270,000+ profiled plasma samples, and 1,000+ peer-reviewed publications, with an 89% coverage rate of FDA-approved protein biomarkers and demonstrably higher data completeness (96.2%) than competing antibody-based platforms.

SomaLogic's corporate trajectory has been turbulent: a 2021 SPAC debut, an approximately 80% stock decline due to profitability challenges, a January 2024 merger into Standard BioTools as a wholly owned subsidiary, and ultimately a January 30, 2026 acquisition by Illumina for $350 million in cash plus up to $75 million in performance-based milestones and revenue-based royalties. As of the acquisition, approximately 250 employees and the Boulder facilities transferred to Illumina, and the SomaScan 11K Assay is being rebranded as Illumina SomaScan Discovery within Illumina's multiomics ecosystem alongside its NGS platforms and DRAGEN software. Standard BioTools retained a 2% royalty on SOMAmer-based NGS library preparation kits for 10 years post-close.

Name

SomaLogic

Legal name

SomaLogic Operating Co., Inc.

Website

https://somalogic.com

Company type

Private

Founded year

2000

Operating status

Acquired

Headcount range

251–500 employees

Short description

SomaLogic is a Boulder-based proteomics company using proprietary SOMAmer aptamer technology to measure up to 11,000 proteins from small blood samples via its SomaScan Platform, serving pharmaceutical trial sponsors, national biobanks, and academic researchers; acquired by Illumina in January 2026.

Ownership category

akta.pro rank

Product category

Clinical Proteomics

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Proteomics platform
• Biomarker discovery
• Aptamer technology
• Clinical diagnostics
• Protein measurement

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SomaScan Assay Services: Fee-for-service proteomics platform provided at SomaLogic's CLIA-certified, CAP-accredited laboratory. Customers send samples for processing and receive proteomic data. Services also available through Authorized Sites worldwide.
2. Reagent Consumables: Single SOMAmer Reagents sold to customers who operate their own SomaScan platforms or Authorized Sites for proteomics analysis.
3. SomaScan Data Consulting Services: Bioinformatics and data analysis services to help customers interpret proteomic data and extract biological insights.
4. SomaLogic Licensing and Royalties: Standard BioTools retained 2% royalty on SOMAmer-based NGS library preparation kits for 10 years following sale to Illumina. Additional revenue-based royalties may apply from the Illumina acquisition.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

SomaLogic provides aptamer-based proteomics products and services built on its proprietary SOMAmer reagent technology. Its core commercial offerings include the SomaScan Platform (11K and Select 4K Assays) for high-multiplex protein measurement, the KREX technology for enhanced detection of low-abundance analytes, fee-for-service SomaScan Assay Services run from a CLIA-certified laboratory, SomaSignal clinical diagnostic tests, and Single SOMAmer Reagents sold to research customers. The offering is targeted at pharmaceutical and biotechnology companies, academic research institutions, national biobanks, and clinical research organizations.

Product overview

SomaLogic offers a unified proteomics platform centered on the SomaScan Platform, which uses proprietary SOMAmer® Reagent aptamer technology to enable high-plex protein measurement. The core portfolio includes the SomaScan 11K Assay (11,000 proteins) and SomaScan Select 4K Assay (4,000 proteins) for broad and targeted proteomic coverage, alongside KREX™ Technology for high-plex antibody profiling. The company operates a fee-for-service model through its CLIA-certified, CAP-accredited laboratory and a global network of Authorized Sites. Supporting products include SomaScan Panels for targeted applications, SomaSignal Tests for biomarker research, and digital tools including the SomaScan Menu database, DataDelve™ Statistics software, and Life Sciences Customer Portal for study management.

Differentiator

Problem solved

Functional benefit

Brands

• SomaScan: Aptamer-based proteomics platform capable of measuring 11,000 proteins from a 55-µL sample. Available in 5K and 11K assay versions.
• SomaScan Assay Services
• SomaSignal Tests
• KREX
• SOMAmer Reagents

Products and services

• SomaScan Platform The SomaScan Platform is SomaLogic's flagship aptamer-based proteomics offering, enabling simultaneous measurement of thousands of protein analytes from small biological samples. It is targeted at pharmaceutical and biotechnology companies, academic medical centers, national biobanks, and clinical research organizations for biomarker discovery, translational research, and clinical proteomics applications.
• SomaScan 11K Assay The SomaScan 11K Assay is a high-multiplex proteomic assay that measures approximately 11,000 protein analytes from a single 55 μL sample with a ~5% median coefficient of variation and a 10-log dynamic range. It is sold to pharmaceutical and biotech R&D teams, academic researchers, and biobank programs for large-scale biomarker discovery and population proteomics studies.
• SomaScan Select 4K Assay The SomaScan Select 4K Assay is a 4,000-analyte configuration of the SomaScan proteomic assay, offering a higher-throughput, focused panel for translational and clinical research. It is targeted at customers needing a more targeted proteomic profile with the reproducibility and scalability of the SomaScan Platform.
• KREX Technology KREX (Kinetic Rate Enhancement) is a proprietary SomaLogic technology that enhances detection of lower-abundance protein analytes, expanding the dynamic range and biological coverage of the SomaScan Platform. It is offered as part of SomaLogic's proteomics solutions for discovery and translational research customers.
• SomaScan Assay Services SomaScan Assay Services is a fee-for-service offering in which SomaLogic runs SomaScan proteomic profiling on customer samples at its CLIA-certified laboratory. The service is targeted at pharmaceutical and biotech sponsors, academic investigators, biobanks, and clinical research organizations that need access to high-multiplex proteomics without internal assay capability.
• SomaSignal Tests SomaSignal Tests are clinical diagnostic tests developed from SomaLogic's proteomics platform, leveraging protein signatures measured by the SomaScan Assay to produce clinical outputs. They are positioned for use by healthcare providers and clinical research customers.
• Single SOMAmer Reagents Single SOMAmer Reagents are individual Slow Off-rate Modified Aptamer reagents sold to research customers for custom assay development, targeted protein measurement, and integration into customer-defined workflows. They are targeted at proteomics researchers and assay developers.
• Illumina Protein Prep Illumina Protein Prep is an NGS-based protein identification kit co-developed with Illumina that allows SOMAmer-captured protein targets to be read out on Illumina sequencing platforms. It is targeted at customers who want to combine aptamer-based protein capture with next-generation sequencing readouts.

Quantifiable outcome

• 96.2% data completeness vs 35-60% for competing platforms in independent comparison study
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and major.

• NovartiscoreStrategic or Co-development Partner · 26 July 2022World-class strategic partner collaborating on proteomics research and drug discovery. Novartis utilizes SomaScan Platform for clinical studies in multiple therapeutic areas.
• NEC CorporationcoreStrategic or Co-development PartnerStrategic partnership for proteomics applications, combining NEC's technology capabilities with SomaLogic's proteomics platform for data-driven health insights.
• AgilentcoreTechnology or IntegrationTechnology partner providing complementary laboratory solutions integrated with SomaLogic's proteomics platform for comprehensive research workflows.
• Leeds Teaching Hospitals NHS TrustcoreStrategic or Co-development PartnerStrategic partner in precision medicine research, combining clinical expertise with SomaScan proteomics for disease research and biomarker discovery.
• OtsukacoreStrategic or Co-development PartnerStrategic pharmaceutical partnership for proteomics applications in drug development and clinical research across therapeutic areas.
• IlluminacoreStrategic or Co-development PartnerPartnership began in late 2021 for proteomics co-development. SomaLogic's SomaScan technology integrated with Illumina's NGS ecosystem. Illumina completed acquisition of SomaLogic in January 2026 for $350M upfront plus potential $75M milestones.
• Vanderbilt University Medical CentermajorStrategic or Co-development PartnerBioVU biobank providing over 250,000 genomes with rich clinical data for Illumina's Alliance for Genomic Discovery project, with plans to include proteomics and spatial transcriptomics data.
• Alnylam PharmaceuticalsmajorStrategic or Co-development PartnerPartner in Alliance for Genomic Discovery expanding genomic dataset to over 250,000 genomes for drug target discovery in diverse populations.
• Genomics EnglandmajorStrategic or Co-development PartnerNational genomics program utilizing Illumina Protein Prep proteomics technology for large-scale population health research.
• PRECISE-SG100KmajorStrategic or Co-development PartnerSingapore national biobank program integrating proteomics with genomic data for precision medicine research.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Olink Holding (now part of Thermo Fisher Scientific): Olink's proximity extension assay-based Explore and Target platforms are the most direct head-to-head competitor to SomaScan in high-plex plasma proteomics, used by the same pharma trial and biobank customers and benchmarked against SomaScan in published precision studies.

Emerging players

• Seer: Seer's Proteograph product suite uses engineered nanoparticle capture plus mass spectrometry to deliver deep, unbiased plasma proteomics, representing an alternative high-plex approach competing for the same biomarker discovery and population proteomics budgets as SomaScan.
• Quanterix: Quanterix's Simoa single-molecule array technology delivers ultra-sensitive protein detection at lower plex, frequently used in neurodegeneration and oncology biomarker studies that overlap with SomaScan's SomaSignal test menu.
• 10x Genomics: 10x Genomics' single-cell and spatial transcriptomics platforms (Chromium, Xenium, Visium) compete for multi-omic pharma research budgets and increasingly integrate proteomics readouts that overlap with SomaLogic's customer use cases.

Broad incumbents

• Standard BioTools: Standard BioTools was SomaLogic's parent company from January 2024 until the Illumina sale; its mass cytometry (CyTOF) and microfluidics platforms serve overlapping pharma and academic customers, and its Discovery Lab complements SomaScan services for multi-omic profiling.
• Bio-Techne: Bio-Techne offers antibody-based proteomics reagents (including the Simple Western and Ella platforms) and ELISA kits that compete for protein biomarker measurement budgets in pharma and academic labs where SomaScan assays are also used.
• Meso Scale Diagnostics: MSD's electrochemiluminescence-based multiplex immunoassays are widely used in pharma clinical trials and biomarker validation, representing the incumbent high-sensitivity antibody-based alternative to SomaScan's aptamer-based platform.
• Bruker (NanoString Spatial Biology): Bruker's acquisition of NanoString brings the GeoMx and CosMx spatial proteomics platforms into a broader proteomics and life sciences portfolio, competing with SomaScan-adjacent workflows in pharma biomarker discovery and translational research.
• Thermo Fisher Scientific (Life Sciences Mass Spectrometry): Thermo Fisher's Orbitrap mass spectrometry instruments and Olink proteomics franchise (post-acquisition) make it the dominant incumbent in mass spec-based proteomics, an alternative workflow competing for SomaScan's pharma and academic customers.

Others

• Abcam: Abcam supplies antibody-based research reagents and validated assay kits that underpin traditional proteomics workflows; while not a direct SomaScan competitor, it serves the same researcher and pharma customer base for protein biomarker studies.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SomaLogic

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds16 records

Investors37 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SomaLogic